Determining a safe pre‐transfusion protocol for multiple myeloma patients on anti‐ <scp>CD38</scp> treatment

Low alloimmunisation suggests NHS Lothian protocol for transfusion of daratumumab patients is safe. Extended phenotyping of patients pre-treatment may be extensive and unnecessary due to the low alloimmunisation rate. Implementation of sCD38 reagent into pre-transfusion testing can reduce extensive pre-treatment testing and improve the safety of transfusion by exclusion of alloantibodies in daratumumab patients.